Myfortic (Mycophenolic Acid)

Mycophenolic Acid, the active ingredient in Myfortic, is an immunosuppressant presented as an enteric‑coated tablet for oral use. It works by inhibiting lymphocyte proliferation and is indicated for the prevention of organ rejection in renal, heart and liver transplant patients.

GNH USA supplies Myfortic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Myfortic (mycophenolate sodium) is used in transplantation medicine to suppress immune‑mediated organ rejection.

- Renal transplantation: helps prevent acute and chronic rejection of the transplanted kidney. - Heart transplantation: reduces risk of graft rejection and supports long‑term graft survival. - Liver transplantation: aids in preventing rejection of the transplanted liver and maintaining graft function.

Myfortic may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Gastrointestinal upset: nausea, vomiting, diarrhea, or abdominal pain. - Infections: increased susceptibility to bacterial, viral or fungal infections. - Hematologic changes: anemia, leukopenia, or thrombocytopenia. - Headache: mild to moderate headache episodes. - Elevated liver enzymes: mild transaminase elevations.

Serious or Rare Side Effects: - Severe infection: opportunistic infections such as CMV or PCP. - Progressive multifocal leukoencephalopathy (PML): rare demyelinating disease. - Nephrotoxicity: worsening renal function. - Malignancy: increased risk of post‑transplant lymphoproliferative disorder. - Life‑threatening hypersensitivity: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing Myfortic, clinicians should consider several safety and handling precautions. - Monitor blood counts: regular CBC to detect leukopenia or anemia. - Assess renal function: adjust therapy if creatinine rises. - Evaluate liver enzymes: periodic LFTs for hepatotoxicity. - Infection vigilance: screen for latent infections and vaccinate appropriately. - Pregnancy and lactation: avoid use unless benefits outweigh risks; discuss with specialist. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Myfortic can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Antimetabolites (e.g., azathioprine): additive bone‑marrow suppression. - Live vaccines: increased risk of severe infection. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce mycophenolate exposure.

Moderate Interactions (Monitor Closely): - Antacids or proton pump inhibitors: may affect absorption of the enteric‑coated tablet. - ACE inhibitors or ARBs: combined use may increase risk of renal impairment. - Non‑live vaccines: monitor immune response.